MODERN APPROACHES TO RISK ASSESSMENT, MECHANISMS OF DEVELOPMENT AND PRINCIPLES OF TREATMENT FOR ARTERIAL HYPERTENSION IN CHRONIC KIDNEY DISEASE
Introduction: chronic kidney disease (CKD) is an independent risk factor for the development of circulatory diseases and cardiovascular complications. Hypertension due to nephrology diseases is the most common cause of symptomatic hypertension.
Aim: to conduct systematic research of scientific information on risk assessment, development mechanisms and principles of treatment for arterial hypertension in chronic kidney disease.
Search strategy. The search for relevant scientific publications was carried out in databases of evidence-based medicine (PubMed, Cochrane Library, ResearchGate, Google Scholar), and the electronic scientific libraries (CyberLeninka, e-library).
Inclusion criteria were studies carried out in people published in English, Russian, full-text versions of articles. Preference was given to studies of high methodological quality (meta-analyzes, systematic reviews and cohort studies). In case of absence such types of publications the study included the publication of case-control and cross-sectional design.
Key words for search were: “chronic kidney disease and hypertension”, “chronic kidney disease and complications”, “chronic kidney disease and outcomes”, “hypertension and treatment and chronic kidney disease”. A total of 217 literary sources were found, of which 64 articles were selected for subsequent analysis.
Results: The research findings are characterized by availability of sufficient number of systematic reviews, randomized clinical trials, clinical guidelines, which allows us to make conclusions regarding the risk assessment, development mechanisms and principles of treatment of AH in CKD.
Conclusions: hypertension is one of the most important risk factors for the development of chronic renal damage with a decrease in kidney function. In turn, CKD of any etiology accompanied by the development of hypertension, its severity is directly related to the risk of developing terminal renal failure. This necessitates an integrated approach to the treatment of hypertension. Only timely detection and adequate cardiac and nephro-protective therapy can slow down progression of pathology.
Кirill S. Milchakov
Graduate School of Health Management, First Moscow State Medical University named after I.M. Sechenov, Ministry of Health of the Russian Federation, Moscow, Russian Federation
Grzhibovskiy A.M., Ivanov S.V. Poperechnye (odnomomentnye) issledovaniya v zdravookhranenii [Cross-sectional (one-stage) studies in public health]. Nauka i zdravookhranenie [Science and Healthcare]. 2015, №2. pp. 5-18.
Grzhibovskiy A.M., Ivanov S.V., Gorbatova M.A. Issledovaniya tipa «sluchay-kontrol'» v zdravookhranenii [Case-control studies in health care]. Nauka i zdravookhranenie [Science and Healthcare]. 2015, №4. pp. 5-17.
Natsional'nye rekomendatsii po profilaktike, diagnostike i lecheniyu arterial'noy gipertonii [National recommendations for the prevention, diagnosis and treatment of hypertension] .- M., 2008. 37 p.
Nefrologiya. Natsional'noe rukovodstvo [Nephrology. National guideline] / Pod red. N.A. Mukhina. GEOTAR Media, M. 2009. 720 p.
Panina I.Yu., Petrishchev N.N., Smirnov A.V. Arterial'naya gipertenziya i endotelial'naya disfunktsiya pri KhBP [Arterial hypertension and endothelial dysfunction in CKD]. Arterial'naya gipertenziya [Arterial hypertension]. 2006, №12. pp.352-357.
Shvetsov M.Yu., Bobkova I.N., Kolina I.B., Kamyshova E.S. Sovremennye printsipy diagnostiki i lecheniya khronicheskoy bolezni pochek: metodicheskoe rukovodstvo dlya vrachey [Modern principles of diagnosis and treatment of chronic kidney disease: a methodical guide for doctors]. Saratov, 2011.46 p.
Shutov A.M., Saenko Yu.V. Pleotropnye kardioprotektivnye effekty eritropoetina [Pleiotropic cardioprotective effects of erythropoietin]. Nefrologiya [Nephrology]. 2006. T. 10, №4. S. 18-22.
2013 ambulatory blood pressure monitoring recommendations for the diagnosis of adult hypertension, assessment of cardiovascular and other hypertension-associated risk, and attainment of therapeutic goals. Chronobiol Int. 2013.Vol.30, №3.Р.355-410.
Arulkumaran N. Pulse pressure and progression of chronic kidney disease. J. Nephrol. 2010. Т. 23, № 2. pp. 189–193.
Bakris G. JS ISH-ISN-2 role of the kidney in resistant hypertension: why so resistant to BP control in CKD patients? J Hypertens. 2016. Vol.34. Suppl 1. ISH Abstract Book. e191.
Bauer A., Rizas K.D. Renal denervation for resistant hypertension. N Engl J Med. 2014. Vol.371, №2. Р.183-184.
Bhatt D.L., Bakris G.L. Renal denervation for resistant hypertension. N Engl J Med. 2014. Vol. 371, №2. Р.184.
Boesen E.I. Endothelin receptors, renal effects and blood pressure. Curr Opin Pharmacol. 2015. Vol.21. Р. 25-34.
Boutari C., Stavropoulos K., Imprialos K., Doumas M., Karagiannis A. PATHWAY-2: spironolactone for resistant hypertension. Lancet. 2016. Vol.387(10026). Р.1371-1372.
Boyle S.M., Berns J.S. Erythropoietin and resistant hypertension in CKD. Semin Nephrol. 2014. Vol.34, №5. Р.540-549.
Böhlke M, Barcellos FC. From the 1990s to CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) trial results and beyond: does stenting have a role in ischemic nephropathy? Am J Kidney Dis. 2015. Vol. 65, №4. Р.611-22.
Braam B., Taler S.J., Rahman M., Fillaus J.A., Greco B.A., Forman J.P., Reisin E., Cohen D.L., Saklayen M.G., Hedayati S.S. Recognition and Management of Resistant Hypertension. Clin J Am Soc Nephrol. 2017. Vol.12, №3. Р.524-535.
Campese V.M. Pathophysiology of resistant hypertension in chronic kidney disease. Semin Nephrol. 2014.Vol.34, №5.Р.571-576.
Chronic Kidney Disease Prognosis Consortium, Matsushita K., van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality: a collaborative meta-analysis. Lancet. 2010. Vol. 375. Р. 2073-2081.
Constantine G.R., Ranasinghe P., Weeratunga P., et al. Addition of Propranolol in Resistant Arterial hypertension Treatment (APROPRIATE study): study protocol for a randomized double-blind placebo-controlled trial. Trials. 2017. Vol.18, №1- Р.124.
Dale A., Hartley P., Goldacre B.; COMPare project team. PATHWAY-2: spironolactone for resistant hypertension. Lancet. 2016. Vol.387(10026). Р.1372-1373.
Davenport A.P., Hyndman K.A., Dhaun N., Southan C., Kohan D.E. et al. Endothelin. Pharmacol Rev. 2016. Vol.68, №2.Р.357-418.
Digne-Malcolm H., Frise M.C., Dorrington K.L. How Do Antihypertensive Drugs Work? Insights from Studies of the Renal Regulation of Arterial Blood Pressure. Front Physiol. 2016. Vol.29, №7. Р.320.
Drexler Y.R., Bomback A.S. Definition, identification and treatment of resistant hypertension in chronic kidney disease patients. Nephrol Dial Transplant. 2014. Vol. 29, №7. Р.1327-1335.
Ewen S., Böhm M., Mahfoud F. Long-Term Follow-Up of Baroreflex Activation Therapy in Resistant Hypertension: Another Piece of the Puzzle? Hypertension. 2017. Vol.69, №5. Р.782-784.
Garofalo C., Borrelli S., Pacilio M., Minutolo R., Chiodini P., De Nicola L., Conte G. Hypertension and Prehypertension and Prediction of Development of Decreased Estimated GFR in the General Population: A Meta-analysis of Cohort Studies. Am J Kidney Dis. 2016. Vol. 67, №1. Р.89-97.
Gheewala P.A., Zaidi S.T., Jose M.D., Bereznicki L., Peterson G.M., Castelino R.L. Effectiveness of targeted screening for chronic kidney disease in the community setting: a systematic review. J Nephrol. 2017 [Epub ahead of print]
Fox C.S. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012. Т. 380, № 9854. Р.1662–1673.
Hamrahian S.M. Management of Hypertension in Patients with Chronic Kidney Disease. Can J Cardiol. 2017. Vol.33, №5. Р. 557-576
Hamrahian S.M, Falkner B. Hypertension in Chronic Kidney Disease. Adv Exp Med Biol. 2016. P. 307-325.
Hering D., Trzebski A., Narkiewicz K. Recent advances in the pathophysiology of arterial hypertension: potential implications for clinical practice. Pol Arch Intern Med. 2017. Vol.127, №3. Р.195-204.
Jager K.J., Fraser S.D.S. The ascending rank of chronic kidney disease in the global burden of disease study. Nephrol Dial Transplant. 2017. Vol.32 (suppl 2). ii121-ii128.
Jha V., Garcia-Garcia G., Iseki K., et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013. Vol. 382. Р. 260–272.
Judd E., Calhoun D.A. Management of hypertension in CKD: beyond the guidelines. Adv Chronic Kidney Dis. 2015. Vol.22, №2. Р.116-122.
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Inter. (Suppl.). 2012., № 2. P. 177-205
Kulenthiran S., Ewen S., Böhm M., Mahfoud F. Hypertension up to date: SPRINT to SPYRAL. Clin Res Cardiol. 2017 Mar 22. P.475-484.
Kuznik A., Mardekian J., Tarasenko L. Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001-2010. BMC Nephrol. 2013.Т. 14, № 1. С.132
Qaseem A. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 2013. Т. 159, № 12. pp. 835–47.
Quack I., Westenfeld R. Cardiovascular morbidity and mortality in patients with kidney disease. Dtsch Med Wochenschr. 2016. Vol.141, №24. Р.1771-1776.
Leem J., Lee I.K. Mechanisms of Vascular Calcification: The Pivotal Role of Pyruvate Dehydrogenase Kinase 4. Endocrinol Metab (Seoul). 2016. Vol. 31, №1. Р.52-61.
Liu X., Liu X., Huang W., Leo S., Li Y., Liu M., Yuan H. Evening -versus morning- dosing drug therapy for chronic kidney disease patients with hypertension: a systematic review. Kidney Blood Press Res. 2014. Vol.39, №5. Р.427-440.
Liyanage T., Ninomiya T., Jha V., et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015. Vol. 385. Р. 1975–1982.
McGaughey T.J., Fletcher E.A., Shah S.A. Impact of Antihypertensive Agents on Central Systolic Blood Pressure and Augmentation Index: A Meta-Analysis. Am J Hypertens. 2016. Vol.29, №4.-Р.448-457.
Mahmoodi B.K. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012. Т. 380, № 9854. pp. 1649–61
Matsushita K., van der Velde M, et al. Chronic Kidney Disease Prognosis Consortium, Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality: a collaborative meta-analysis. Lancet. 2010. Vol. 375. Р. 2073–2081.
Matsushita K., Coresh J., Sang Y., Chalmers J., Fox C., et al. CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015. Vol.3, №7. Р.514-525.
Nammas W., Koistinen J., Paana T., Karjalainen P.P. Renal sympathetic denervation for treatment of patients with heart failure: summary of the available evidence. Ann Med. 2017. Vol. 10. Р.1-12.
Raman V.K., Tsioufis C., Doumas M., Papademetriou V. Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work? Curr Treat Options Cardiovasc Med. 2017. Vol.19, №5. Р.39.
Sarafidis P.A., Georgianos P.I., Zebekakis P.E. Comparative epidemiology of resistant hypertension in chronic kidney disease and the general hypertensive population. Semin Nephrol. 2014. Vol.34, №5. Р.483-491.
Sim J.J., Bhandari S.K., Shi J., Reynolds K., Calhoun D.A., Kalantar-Zadeh K., Jacobsen S.J. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015. Vol.88, №3. Р.622-632.
Sternlicht H., Bakris G.L. The Kidney in Hypertension. Med Clin North. 2017. Vol. 101, №1. Р. 207-217.
Sukkar L., Hong D., Wong M.G., Badve S.V., Rogers K., Perkovic V., Walsh M., Yu X., Hillis G.S., Gallagher M., Jardine M. Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis. BMJ. 2016.Vol. 355. Р.5599.
Tanner R.M,. Calhoun D.A., Bell E.K., Irvin M.R., Lackland D.T., Oparil S., Warnock D,. Muntner P. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013. Vol.8, №9. Р.1583-1590.
Tataru A.P., Barry A.R. A Systematic Review of Add-on Pharmacologic Therapy in the Treatment of Resistant Hypertension. Am J Cardiovasc Drugs. 2017 Mar 27. P.311-318
Thomopoulos C., Katsimagklis G., Archontakis S., Skalis G., Makris T. Optimizing the management of uncontrolled hypertension: what do triple fixed- dose drug combinations add? Curr Vasc Pharmacol. 2017. P. 37-46.
Tsioufis C., Dimitriadis K., Kordalis A., Doumas M., Konstantinidis D., Kalos T., Mahfoud F., Papademetriou V., Tousoulis D. Renal denervation therapy: Can it contribute to better blood pressure control in hypertension? Curr Vasc Pharmacol. 2017. P. 145-158.
Tsuruya K., Eriguchi M. Cardiorenal syndrome in chronic kidney disease. Curr Opin Nephrol Hypertens. 2015. Vol.24, №2. Р.154-162.
Tsuruya K., Eriguchi M., Yamada S., Hirakata H., Kitazono T. Cardiorenal Syndrome in End-Stage Kidney Disease. Blood Purif. 2015. Vol.40, №4. Р.337-343.
Weber M.A., Black H., Bakris G., Krum H., et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009. Vol.374 (9699). Р.1423-1431.
Widimský J. PATHWAY-2 Study: spironolactone vs placebo, bisoprolol and doxazosin to determine optimal treatment of resistant hypertension. Spironolactone high effective in lowering blood pressure in drug resistant hypertension. Vnitr Lek. 2015. Vol.61, №12. Р.1067-1071.
Williams B., MacDonald T.M., Morant S.V., Brown M.J. PATHWAY-2: spironolactone for resistant hypertension - Authors' reply. Lancet. 2016. Vol. 387 (10026). Р.1373-1374.
Wolley M.J., Stowasser M. Resistant Hypertension and Chronic Kidney Disease: a Dangerous Liaison. Curr Hypertens Rep. 2016. Vol.18, №5. Р.36.
Vemulapalli S., Tyson C.C., Svetkey L.P. Apparent treatment-resistant hypertension and chronic kidney disease: another cardiovascular-renal syndrome? Adv Chronic Kidney Dis. 2014. Vol. 21, №6. Р.489-499.
Verdalles Ú., Goicoechea M., Garcia de Vinuesa S., Quiroga B., Galan I., Verde E., Perez de Jose A., Luño J. Prevalence and characteristics of patients with resistant hypertension and chronic kidney disease. Nefrologia. 2016.Vol.36, №5. Р.523-529
Bibliography link
Milchakov К.S. Modern approaches to risk assessment, mechanisms of development and principles of treatment for arterial hypertension in chronic kidney disease. Nauka i Zdravookhranenie [Science & Healthcare]. 2017, 5, pp. 113-128